Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin's lymphoma

Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545.

Cervantes F, Shu XO, McGlave PB et al. Autologous bone marrow transplantation for non-transformed low grade non-Hodgkin's lymphoma. Bone Marrow Transplant 1995; 16: 387–392.

Bierman PJ, Vose JM, Anderson JR et al. High dose therapy with autologous hematopoietic rescue for follicular low grade non-hodgkin's lymphoma. J Clin Oncol 1997; 15: 445–450.

Krackhardt A, Gribben JG. Stem cell transplantation for indolent lymphoma. Curr Opin Hematol 1999; 6: 388–393.

Shepherd JD, Barnett MJ, Connors JM et al. Allogeneic bone marrow transplantation for poor prognosis non-Hodgkin's Lymphoma. Bone Marrow Transplant 1993; 12: 591–596.

Toze CL, Shepherd JD, Connors JM et al. Allogeneic bone marrow transplantation for low grade lymphoma and chronic lymphocytic leukemia. Bone Marrow Transplant 2000; 25: 605–612.

Van Besien K, Sobocinski KA, Rowlings PA et al. Allogeneic bone marrow transplantation for low grade lymphoma. Blood 1998; 92: 1832–1836.

Verdonck LF, Dekker AW, Lokhorst HM et al. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low grade non-Hodgkin's lymphoma. Blood 1997; 90: 4201–4205.

Van Besien KW, de Lima M, Giralt SA et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft versus lymphoma effect. Bone Marrow Transplant 1997; 19: 977–982.

Jones RJ, Ambinder RF, Piantadosi S et al. Evidence of a graft versus lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991; 77: 649–653.

Verdonck LF. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low grade non-Hodgkin's lymphoma: updated results of the Utrecht experience. Leuk Lymphoma 1999; 34: 129–136.

Schimmer AD, Jamal S, Messner H et al. Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin's lymphoma (NHL): results of a provincial strategy. Bone Marrow Transplant 2000; 26: 859–864.

Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70: 1382–1388.

Copelan EA, Biggs JC, Szer J et al. Allogeneic bone marrow transplantation for acute myelogenous leukemia, acute lymphoblastic leukemia and multiple myeloma following preparation with busulfan and cyclophosphamide (BuCy2). Semin Oncol 1993; 20 (Suppl. 14): S33–S38.

Brodsky I, Biggs JC, Szer J et al. Treatment of chronic myelogenous leukemia with allogeneic bone marrow transplantation after preparation with busulfan and cyclophosphamide (BuCy2): an update. Semin Oncol 1993; 20 (Suppl. 14): S27–S31.

Van der Jagt RHC, Appelbaum FR, Petersen FB et al. Busulfan and cyclophosphamide as a preparative regimen for bone marrow transplantation in patients with prior chest radiotherapy. Bone Marrow Transplant 1991; 8: 211–215.

Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729–735.

Hess AD, Kennedy MJ, Ruvolo PP et al. Antitumor activity of syngeneic/autologous graft versus host disease. Ann N Y Acad Sci 1995; 770: 189–202.

Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

Mantel N. Evaluation of survival data and two new rank order statistics arising in its considerations. Cancer Chemother Rep 1966; 50: 163–170.

McDonald GB, Hinds MS, Fisher LB et al. Venoocclusive disease of the liver and multi organ failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255–267.

Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft versus host disease in human recipients of marrow from HLA matched sibling donors. Transplantation 1974; 18: 295–304.

Shulman HM, Sale GE, Lerner KG et al. Chronic cutaneous graft versus host disease in man. Am J Pathol 1978; 91: 545–570.

De Magalhaes-Silverman M, Lister J, Rybka W et al. Busulfan and cyclophopshamide (Bu/Cy2) as preparative regimen for patients with lymphoma. Bone Marrow Transplant 1997; 19: 777–781.

Weaver CH, Schwartzberg L, Rhinehart S et al. High dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low grade non-Hodgkin's lymphoma. Bone Marrow Transplant 1998; 21: 383–389.

Avalos BR, Klein JL, Kapoor N et al. Preparation for marrow transplantation in Hodgkin's disease and non-Hodgkins lymphoma using Bu/Cy. Bone Marrow Transplant 1993; 12:133–138.

Appelbaum FR, Anderson JA. Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia 1998; 12 (Suppl. 1): S25–S29.

Andersson BS, Gajewski J, Donato M et al. Allogeneic stem cell transplantation for AML and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy). Bone Marrow Transplant 2000; 26 (Suppl. 2): S35–S38.

Ringden O, Remberger M, Ruutu T et al. Increased risk of chronic graft versus host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic bone marrow transplantation group. Blood 1999; 93: 2196–2201.